Custom-Made vaccine aims to boost immune attack on kidney tumors
NCT ID NCT07686744
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This early-stage trial tests whether a personalized vaccine, made from each patient's unique tumor mutations, can safely boost the effects of the immunotherapy drug pembrolizumab in people with advanced kidney cancer. The vaccine is designed to train the immune system to recognize and attack cancer cells. The study enrolls 5-8 adults whose cancer has stopped responding to standard treatment, and will primarily check for side effects while also tracking tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- personalized neoantigen peptide vaccine (Neo-RCC) plus pembrolizumab
- What this could lead to
- If successful, this combination could improve response rates and extend disease control for advanced kidney cancer patients who have limited options.
- What could go wrong
- This is a very early Phase 1 trial with only 8 participants, so safety and effectiveness are not yet proven. The vaccine is custom-made for each patient, which is complex and may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can a blast of radiation make immunotherapy work better against kidney cancer?
- Can reprogrammed immune cells take on hard-to-treat kidney cancer?
- Can a drug duo outsmart resistant lymphomas?
- Robot surgeon takes on kidney and prostate operations
- Could a lighter immunotherapy schedule keep advanced cancers in check?